This paper compares results for two emerging technologies for the delivery of amorphous drug to those for a third established technology. Specifically, the goal was to improve the dissolution rate and oral bioavailability of flubendazole (FLU) using three approaches: (1) a standard spray-dried dispersion with hydroxypropyl methylcellulose (HPMC) E5 or polyvinylpyrrolidone-vinyl acetate 64 (the established technology); (2) a modified process spray-dried dispersion with either HPMC E3 or hydroxypropyl methylcellulose acetate succinate (HPMCAS-M); and (3) a formulation confining FLU in ordered mesoporous silica (OMS). Preparation, characterization, and optimization of the three dosage forms is described, as are the results of in vitro testing.